Metabolic consequences of 5-year growth hormone (GH) therapy in children treated with GH for idiopathic short stature

Paul Saenger, Kenneth M. Attie, Joan Dimartino-Nardi, Raymond Hintz, Lindley Frahm, James W. Frane, A. J. Johanson, J. Baptista, J. Kuntze, R. Blizzard, J. Cara, S. Chernausek, M. Geffner, J. Gertner, N. Hopwood, S. Kaplan, B. Lippe, L. Plotnick, A. Rogol

Research output: Contribution to journalArticlepeer-review

38 Scopus citations


In a multicenter study the metabolic effects of 5 yr of GH therapy in children with idiopathic short stature were evaluated. Patients received 0.3 mg/kg · week recombinant human GH. Of the 121 patients who entered the study, data for 62 were analyzed at the final 5 yr point. Routine laboratory determinations were available for all 62 subjects at the 5 yr point. Special laboratory determinations, such as postprandial glucose and insulin, were available for only a subset of patients. Mean insulin-like growth factor I levels rose to 283 ± 101 μg/L, within the normal range using age- appropriate reference standards. T4, cholesterol, triglycerides, blood chemistries, and blood pres- sure showed no significant changes during the 5- yr period. Mean baseline and 2-h postprandial glucose levels remained unchanged. Both fasting and postprandial insulin levels rose substantively from low normal levels to the normal range (median, 4.9-43 mU/L). Mean hemoglobin A(1c) levels remained within the normal range throughout the study. In summary, careful monitoring has not revealed any currently discernible metabolic side-effects of clinical significance after GH therapy in this 5-yr study of children with idiopathic short stature.

Original languageEnglish (US)
Pages (from-to)3115-3120
Number of pages6
JournalJournal of Clinical Endocrinology and Metabolism
Issue number9
StatePublished - Nov 14 1998

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical


Dive into the research topics of 'Metabolic consequences of 5-year growth hormone (GH) therapy in children treated with GH for idiopathic short stature'. Together they form a unique fingerprint.

Cite this